ARS Pharmaceuticals, Inc. Common Stock SPRY
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $27.00 (+380.4% upside)
Key Stats
- Today's Range
- $5.54 – $5.70
- 50-Day Range
- $4.91 – $8.97
- 52-Week Range
- $4.91 – $18.00
- Volume
- 853K shs
- Average Volume
- 1.90 million shs
- Market Cap
- $558.89 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 44.67
- Price / Sales
- 4.78
Short Interest
- Short Interest
- 0.82%
- Days to Cover
- 4.25
Financials (TTM)
- Revenue
- $116.93 million
- Net Income
- $-215,432,000
- Net Margin
- -184.24%
- Return on Equity
- -1721.80%
- Debt-to-Equity
- 7.73
About ARS Pharmaceuticals, Inc. Common Stock
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Related Stocks
Compare head-to-head: SPRY vs LLY·SPRY vs JNJ·SPRY vs ABBV·SPRY vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.